Should I buy AbbVie stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of AbbVie for over three years. Every month, over a million users in the US trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes only and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by AbbVie.

What is AbbVie?

AbbVie Stock Price

The price of AbbVie stock is rising this week. AbbVie shares are currently at $189.70, slightly down $1.10 over the last 24 hours but up 1.31% for the week. The company’s market capitalization stands at $335.09 billion, with an average trading volume of 7.66 million shares over three months. The P/E Ratio is 80.73, dividend yield is 3.53%, and the stock’s beta is 0.49, indicating relatively low volatility. With strong fundamentals and continuing product innovation, AbbVie remains an appealing choice for US investors.

Our full analysis of AbbVie stock

We have thoroughly reviewed AbbVie’s latest financial disclosures and analyzed the stock’s performance trajectory over the past three years. Leveraging a multi-source approach that incorporates proprietary algorithms to synthesize a diverse array of inputs—from financial metrics and technical signals to competitive positioning and market data—we have produced an in-depth, prospective analysis. So, why might AbbVie stock once again become a strategic entry point into the US healthcare sector in 2025?

Recent performance and market context

AbbVie stock has demonstrated substantial resilience and upward traction, closing at $189.70 with a weekly gain of 1.31%. Over the past twelve months, it has posted a robust advance of nearly 16%, decisively outperforming many peers in the sector. This momentum is underscored by a strong bounce from recent support levels after periods of sector volatility, highlighting both the company’s defensive qualities and renewed investor appetite. The US healthcare market remains supported by demographic expansion and a stable reimbursement environment, further bolstering large-cap pharma stocks. Notably, Q1 2025 results outperformed consensus, with analyst guidance for 2025 revised higher, reflecting management’s confidence and sustained growth across new product lines.

• Revenue acceleration from next-generation immunology assets
• Recognition by markets and analysts of AbbVie’s effective post-Humira transition
• Increasing consensus price targets, with an average of $209.12 (+10% vs. current levels)

With the regulatory climate relatively stable and US pharma fundamentals trending positively, AbbVie stands out for its ability to capitalize on secular health sector tailwinds.

Technical analysis

From a technical perspective, AbbVie displays constructive price formation and encouraging momentum signals. The prevailing bullish structure is supported by all key moving averages: the 5-day, 20-day, 50-day, and 200-day averages ($187.09, $187.78, $186.83, and $186.15, respectively) all sit below the current share price, and each is flashing buy signals. The 14-day RSI stands at 57.14, indicating healthy momentum just below overbought territory—leaving room for further appreciation.

MACD remains only slightly positive, suggesting the stock is consolidating after recent gains, while Williams %R at -23.94 reinforces short-term bullishness. Notably, the clear support level at $182.93 has proven reliable, with resistance identified at $188.31 just recently breached—pointing to the possibility of a significant breakout if volume sustains above this area. Technical momentum is likely to capture additional buyers should the uptrend persist, especially as short- and medium-term moving averages provide a robust foundation for future appreciation.

Fundamental analysis

AbbVie’s current value proposition is underpinned by impressive fundamental strength:

• Q1 2025 revenues advanced 8.4% year-over-year to $13.34 billion, driven by the dual engines of Skyrizi and Rinvoq—both surging over 50%, more than offsetting the predictable decline in Humira revenues.
• Adjusted EPS grew 6.5% to $2.46, and the company’s raised full-year guidance ($12.09–$12.29 per share) demonstrates management’s commitment to consistent shareholder value.
• The firm’s operating margin remains superior at 42.3%, underscoring operational efficiency even during product transitions.

While the current P/E ratio (80.73 TTM) appears elevated, this figure is inflated by accounting impacts and extraordinary charges; normalized on a forward basis and when considering AbbVie’s robust and diversified late-stage pipeline, valuation becomes far more compelling. The company’s attractive 3.53% dividend yield further enhances total return potential—especially appealing in a low-rate environment.

AbbVie’s competitive advantages extend well beyond numbers:

• Global leadership in immunology and neuroscience
• Deep, innovative pipeline across oncology, neuroscience, and medical aesthetics
• A reputation for successful late-stage clinical execution and regulatory navigation

Its increased investments in US manufacturing and strategic M&A (notably with Capstan Therapeutics and Xilio Therapeutics) amplify its ability to capture market share in high-value areas.

Volume and liquidity

Liquidity remains a hallmark of AbbVie’s investment appeal. With a three-month average daily trading volume of 7.66 million shares and a market capitalization of over $335 billion, the stock exhibits tight spreads and robust order book depth—hallmarks of institutional confidence. This ample liquidity supports both tactical moves and larger strategic allocations, benefiting not only professional asset managers but also retail investors seeking exposure to the sector with confidence in price realization.

A substantial free float, together with steady institutional participation, contributes to dynamic price discovery and limits the risk of illiquidity-driven volatility. In the current landscape, such liquidity is a distinguishing feature, further justifying renewed optimism on entry.

Catalysts and positive outlook

AbbVie’s pipeline of growth opportunities is particularly compelling:

• Rapid uptake of Skyrizi and Rinvoq, now established as blockbuster drugs, underpins near- and mid-term growth, decisively offsetting Humira’s post-patent expiry declines.
• Strategic expansion into obesity therapeutics via the Gubra partnership positions AbbVie for leadership in a high-growth, high-margin segment.
• The acquisition of Capstan Therapeutics strengthens the company’s immunology portfolio, unlocking new frontiers in cell and gene therapy.
• Continued outperformance in neuroscience (notably with Vraylar and Qulipta) diversifies revenue streams and moderates risks associated with single-product dependence.
• Substantial investments in R&D (15.4% of revenue) and in US manufacturing offer a powerful signal of commitment to domestic innovation, resilience, and job creation.
• ESG initiatives—ranging from access to medicines and responsible supply chains to diversity, equity, and inclusion—continue to enhance AbbVie’s recognition among socially responsible investors.

Favorable regulatory and demographic fundamentals in the US, combined with strategic business development and an expanding global footprint, help create a supportive upward context for shareholders. The momentum stemming from analyst upgrades and raised guidance further reinforces the case for a multi-year re-rating of AbbVie.

Investment strategies

AbbVie’s risk-reward profile appears attractive across multiple time horizons:

• Short-term (1–3 months)
• Recent technical breakouts above $188.31 set up the stock for swift upside follow-through
• The approach of Q2 2025 earnings (scheduled July 31) is likely to serve as a catalyst for renewed buying
• Medium-term (3–12 months)
• Ongoing sales traction in immunology and neuroscience, paired with further positive data readouts, should sustain relative outperformance
• The stock trades above all major moving averages, supporting upward technical momentum and targeting the analyst consensus price of $209
• Institutional accumulation and resilient trading volume indicate continued capital inflows
• Long-term (12+ months)
• AbbVie’s track record of innovation, the continued rollout of novel indications, and strong management vision support durable growth
• A reliable dividend and disciplined capital allocation enhance the appeal for total return investors
• Secular demographic trends and increasing healthcare demand position AbbVie to benefit from industry tailwinds for years to come

Entry can be ideal at technical pullbacks toward support ($182–$186) or ahead of key product launches and financial disclosures. For those seeking both defensive qualities and growth potential, AbbVie stands out as a core holding in the healthcare sector.

Is it the right time to buy AbbVie?

AbbVie combines the best elements of growth, resilience, and innovation, offering investors a credible and optimistic path for capital appreciation. Recent performance, elevated by strong guidance and multiple successful product rollouts, justifies renewed interest at today’s levels. With continued leadership in immunology, advancing neuroscience assets, and robust liquidity, the stock may be entering a new bullish phase. Its mix of reliable dividend payments, strategic pipeline development, and strong risk management suggests that AbbVie could outperform in 2025 and beyond. For investors looking to reinforce their exposure to the US healthcare sector with a fundamentally sound and dynamically positioned leader, AbbVie seems to represent an excellent opportunity at this time.

How to buy AbbVie stock in the United States

Buying AbbVie stock online through a regulated US broker is both simple and highly secure. Investors can choose to purchase AbbVie shares directly (for ownership and dividends) or to trade Contracts for Difference (CFDs) that follow the share price without ownership. Each method is accessible from major online trading platforms that meet strict US financial regulations. Whether you want to invest for the long term or seek active trading, a side-by-side broker comparison is available further down the page to guide your decision.

Cash buying

A cash purchase of AbbVie stock means you buy and own the actual shares in your account. Most US brokers charge a fixed commission per order, typically around $0–$10.

Investment Gain Scenario

If the AbbVie share price is $189.70, you can buy around 5.25 shares with a $1,000 stake, including a brokerage fee of around $5.

✔️ Gain scenario:

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading on AbbVie shares allows you to speculate on price movements without owning the underlying stock. This method offers leverage—so you can control a larger market position with less capital—but it also involves the spread costs and overnight financing fees for positions held more than a day.

CFD Gain Scenario Example

You open a CFD position on AbbVie shares, with 5x leverage using $1,000 upfront.

This gives you a market exposure of $5,000.

✔️ Gain scenario:

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Always compare brokers’ fees, spreads, and platform conditions before investing to find the best fit for your needs. Whether you choose cash buying for traditional ownership or CFDs for leverage, the right method depends on your own investment objectives and risk profile—be sure to review the detailed broker comparison further down this page before you start.

Our 7 tips for buying AbbVie stock

The latest news about AbbVie

AbbVie reported a weekly stock price gain of 1.31%, continuing its 2025 upward trend. This positive performance is supported by resilient investor confidence and follows the company’s solid market positioning in the United States, where it maintains a key role in the pharmaceutical sector with widely distributed products.

The company’s Q1 2025 revenue rose 8.4% year-over-year, with exceptional growth in immunology and neuroscience. Strong US sales of Skyrizi and Rinvoq contributed significantly, each posting double-digit increases, reflecting effective execution on new therapeutic franchises critical for AbbVie’s American market share.

AbbVie updated its 2025 earnings guidance upward, raising adjusted EPS expectations to $12.09–$12.29. This revised outlook, disclosed in the company’s official filing, is fueled by strong performance in core segments and robust US operations. It reinforces positive sentiment among Wall Street analysts and aligns with the consensus “Moderate Buy” rating.

The acquisition of Capstan Therapeutics for $2.1 billion further strengthens AbbVie’s pipeline in immunology. The deal is highly relevant to US investors, as it secures future innovation capacity, enhances AbbVie’s strategic competitiveness nationally, and positions the company at the forefront of breakthrough therapies regularly scrutinized by the FDA.

Impressive technical signals reinforce bullish momentum, with all major moving averages indicating a buy signal. The stock’s 5, 20, 50, and 200-day averages remain above key support, while the Williams %R oscillator and neutral RSI signal balanced momentum. This technical picture suggests underlying strength for AbbVie’s shares on US markets.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.